Sentences with phrase «poor clinical outcome»

We demonstrated that ABL kinases promoted tumor - induced osteolysis in part through the osteoclast - activating cytokine IL - 6, increased serum concentrations of which are associated with poor clinical outcome in breast cancer patients (50).

In addition, higher REV - ERBα expression or lower BMAL1 expression both predict poor clinical outcome for human neuroblastoma patients, as determined by publicly available patient survival data from The Children's Hospital of Philadelphia and the University of Cologne, Germany.

Shalowitz and colleagues suggest future studies should focus on defining areas with poor clinical outcomes attributed to geographic factors, and creating a comprehensive national, geographically - linked database on the utilization of gynecologic cancer care and clinical outcomes.

Specific translational studies include: Molecular mechanisms of migration contribute to metastasis and subsequently thought to be central to the cancer progression poor clinical outcome for cancer patients.

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome

This study also found poorer clinical outcomes in asymptomatic patients compared with the clinical outcomes of symptomatic patients in the PAF group but not in the SAF group.

Raleigh's team found that a gene named FOXM1 was at the heart of aggressive meningioma growth, and a signpost of subsequently poor clinical outcomes, including death.

In addition, traumatic brain injury and stroke survivors with apoE4 have consistently poorer clinical outcomes than those without it and are significantly more likely to develop neurological disease.

High REV - ERBa or low BMAL1 predicts poor clinical outcome in N - MYC - driven human neuroblastomas.

Intended primarily for use by patients for whom loss of muscle mass (sarcopenia) may contribute to poor clinical outcomes in chronic illness and decreased quality of life.

The research, published in BMJ Open, also found that mood instability was associated with poorer clinical outcomes.

«This is the first national study to identify specific regions of the United States where residents may be at an increased risk for poor clinical outcomes — including misdiagnoses and late detection — as a result of limited access to specialized gynecologic cancer care,» says David Shalowitz, MD, a fellow in the division of Gynecologic Oncology at the Perelman School of Medicine at the University of Pennsylvania, and lead author on the study.

In the patients they studied, this subtype showed a high likelihood of spreading and progressing to poor clinical outcomes, including fatalities.

Dr. Vogel concludes, «Autoimmune hepatitis patients diagnosed in childhood, those that present with cirrhosis at the time of initial diagnosis or who have SLA / LP antibodies have poor clinical outcomes,; these patients are in need for close surveillance.

«Failure to control localized cancer, confined to the prostate, predicts a poor clinical outcome — PSA recurrence, the spread of cancer beyond the prostate and the likelihood of dying from prostate cancer.»

Failure to control early, localized prostate cancer results in a poor clinical outcome, according to research published in the International Journal of Radiation Oncology Biology Physics.

Reduced FRY expression in many cancer types is associated with more aggressive growth and predicts poor clinical outcomes.

If this study can be replicated in larger trials, then these observations suggest novel biomarkers that can predict for poor clinical outcome, and opens up a new compartment, the stroma, to target new therapies.

Peripheral T - cell lymphomas (PTCL) represent a heterogeneous clinicopathological entity of non-Hodgkin lymphoma with an aggressive disease course and poor clinical outcome.

Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.

This all comes down to the fact that ketones and lactate can increase cancer cell «stemness,» which can drive recurrence, metastasis, and poor clinical outcomes in breast cancer (16).